McMaster University
The Effects of the Commonly Used SSRI, Fluoxetine, on Intestinal Inflammation
Abstract
dc:description.abstractInflammatory bowel disease (IBD), which encompasses Crohn's disease and ulcerative colitis, is characterized by chronic inflammation of the gastrointestinal (GI) tract. In addition to a variety of GI symptoms, IBD patients experience higher rates of anxiety and depression than the general population and are often prescribed selective serotonin reuptake inhibitors (SSRIs) to combat this. These drugs alter serotonin (5-hydroxytryptamine, 5-HT) signaling by blocking the 5-HT reuptake transporter (SERT). Previous research has shown elevated 5-HT levels, as well as altered expression of 5-HT receptors and the 5-HT rate-limiting enzyme, tryptophan hydroxylase 1 (Tph1), have been linked to exacerbated intestinal inflammation, raising concerns about the effects of SSRIs in IBD. This study aims to determine if the commonly prescribed SSRI, fluoxetine, can influence the severity of intestinal inflammation by modulating immune cell function and the gut microbiota. To better reflect the relapsing and remitting characteristics of IBD, we evaluated the effects of the SSRI fluoxetine on intestinal inflammation using a chronic dextran sulfate sodium induced colitis model. Additionally, we investigated whether fluoxetine treatment altered gut microbial composition. Our findings demonstrate that fluoxetine influences colitis severity and may modulate disease outcomes through effects on intestinal inflammatory pathways and the gut microbiota. While fluoxetine treatment likely influenced stool formation through effects on gut motility, it also enhanced the production of inflammatory mediators and downregulated specific markers of intestinal epithelial integrity, particularly at higher doses. Although fluoxetine did not substantially alter overall gut microbial diversity, significant differences were observed in the abundance of specific bacterial taxa. These findings suggest potential detrimental effects of chronic SSRI use in relation to gut inflammation and highlight the need for further investigations to better understand the role of SSRIs in the context of IBD.
Degree
thesis:*- Department dc:contributor.department
- Medical Sciences
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Charissa Cheng
- Advisor dc:contributor.advisor
-
- Khan, Waliul
Subjects
dc:subject × 6Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.71548/7684